Zeit	Session	Beitrag	Autoren	Institution	Die Präsentation
Sunday, 9:30 a.m. - 11:00 a.m.	005. Pharmacokinetics of Quinolones in Children and Adults	45. Ex Vivo Serum Protein Binding of BMS-284756: Impact on the Unbound AUC/MIC Ratio for Streptococcus pneumoniae	A. BELLO, D. HOLLENBAUGH, D. GAJJAR, L. CHRISTOPHER, D. GRASELA;	Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ.
Sunday, 9:30 a.m. - 11:00 a.m.	006. Resistance in Bacteria of Gastrointestinal Origin	64. Trends in Antimicrobial Resistance of the Bacteroides fragilis Group over an 11-Year Period (1989-2000)	C. BETRIU1, M. GOMEZ2, I. RODRIGUEZ-AVIAL2, B. A. SANCHEZ2, J. J. PICAZO2;	1Hospital Clinico San Carlos, Madrid, Spain, 2HOSPITAL CLINICO SAN CARLOS, MADRID, Spain.	Poster Ansehen
Sunday, 11:00 a.m. - 12:30 noon	013. Quinolone Resistance	144. In Vitro selection of Resistance to Several Fluoroquinolones (FQs) in Mycoplasma pneumoniae	D. GRUSON1, A. CHARRON1, H. RENAUDIN1, C. BEBEAR1, C. M. BEBEAR2;	1Universite Victor Segalen Bordeaux 2, Bordeaux, France, 2Universite Victor Segalen Bordeaux 2, BORDEAUX, France.
Sunday, 11:00 a.m. - 12:30 noon	013. Quinolone Resistance	148. Mutation Rates of Acinetobacter baumannii against Gemifloxacin, Moxifloxacin and Ciprofloxacin	P. G. HIGGINS1, K. COLEMAN2, S. G. B. AMYES1;	1University of Edinburgh, Edinburgh, United Kingdom, 2GlaxoSmithKline, Collegeville, PA.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 1:30 p.m. - 3:00 p.m.	033. Novel Antibacterials I	352. In Vitro Activity of BB 83698 and Two Other Peptide Deformylase Inhibitors Compared to Ciprofloxacin, Moxfloxacin, Gentamicin and Linezolid against Heterogeneous Glycopeptide Intermediate Staphylococcus aureus (hGISA) and GISA	MANDY WOOTTON1, R. A. HOWE1, A. P. MACGOWAN1, T. R. WALSH2, P. M. BENNETT2;	1BCARE, Bristol, United Kingdom, 2Bristol University, Bristol, United Kingdom.
Sunday, 2:00 p.m. - 4:30 p.m.	042. Emergence and Prevention of Quinolone Resistance	441. The Magnitude of the Pharmacodynamic Parameters which Predict Fluoroquinolone Antibacterial Effect (ABE) and Emergence of Resistance (EoR) Are Not Uniform for All Species	A. P. MACGOWAN, K. E. BOWKER;	BCARE, Bristol, United Kingdom.
Sunday, 2:00 p.m. - 4:30 p.m.	042. Emergence and Prevention of Quinolone Resistance	438. Comparative Activity of Mutant Prevention Concentration (MPC)-Derived Dosages of Moxifloxacin (MXF) and Levofloxacin (LEV) against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model (IVPM)	G. P. ALLEN1, M. J. RYBAK1,2;	1Anti-Infective Res. Lab., Coll. of Pharmacy and Allied Health Sciences, Wayne State Univ., Detroit, MI, 2Sch. of Med., Wayne State Univ., Detroit, MI.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 2:00 p.m. - 4:30 p.m.	042. Emergence and Prevention of Quinolone Resistance	440. The Pharmacodynamics of Emergence of Resistance (EoR) to Moxifloxacin in S. pneumoniae (Sp) and P. aeruginosa (Pa) Explored in an In Vitro Model of Infection	A. P. MACGOWAN, K. E. BOWKER;	BCARE, Bristol, United Kingdom.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 2:00 p.m. - 4:30 p.m.	042. Emergence and Prevention of Quinolone Resistance	441. The Magnitude of the Pharmacodynamic Parameters which Predict Fluoroquinolone Antibacterial Effect (ABE) and Emergence of Resistance (EoR) Are Not Uniform for All Species	A. P. MACGOWAN, K. E. BOWKER	BCARE, Bristol, United Kingdom.	Poster Ansehen
Sunday, 3:00 p.m. - 4:30 p.m.	049. GAR-936 Susceptibility Studies	519. Comparative Activities of GAR-936 and other Antimicrobial Agents against Bacteroides fragilis Group Organisms	C. BETRIU1, I. RODRIGUEZ-AVIAL2, M. GOMEZ2, B. A. SANCHEZ2, J. J. PICAZO2;	1Hospital Clinico San Carlos, Madrid, Spain, 2HOSPITAL CLINICO SAN CARLOS, MADRID, Spain.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	534. WCK 771 A - an Investigational Anti-MRSA Fluoroquinolone (FQ) with Potent Concentration Independent Cidal Action and an Unusual Ability to Kill Slow Growing Staphylococci	D. J. UPADHYAY, M. V. PATEL, S. V. GUPTE, S. K. AGARWAL, M. A. JAFRI, S. S. BHAGWAT, N. J. DE SOUZA, H. F. KHORAKIWALA;	Wockhardt Research Centre, Aurangabad, India.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	535. In Vitro and In Vivo Efficacy of an Investigational Fluoroquinolone (FQ) WCK 771 A against Pneumococci	S. V. GUPTE, M. V. PATEL, S. K. AGARWAL, K. SREENIVAS, S. C. NAIR, R. D. YEOLE, N. J. DE SOUZA, H. F. KHORAKIWALA;	Wockhardt Research Centre, Aurangabad, India.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	541. Antipneumococcal Activities of WCK 771A and WCK 919 (Two New Quinolones) Compared to 12 Other Agents Against 177 Quinolone-Susceptible Pneumococci	GLENN A. PANKUCH1, M. JACOBS2, H. KHORAKIWALA3, N. DE SOUZA3, M. PATEL3, P. APPELBAUM1;	1Hershey Medical Center, Hershey, PA, 2Case Western Reserve University, Cleveland, OH, 3Wockhardt Research Centre, Aurangabad, India.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	542. Activities of WCK 771A and WCK 919, Two Experimental Quinolones, Compared with Five Other Quinolones against Quinolone Susceptible and Resistant Staphylococci	M. R. JACOBS1, S. BAJAKSOUZIAN1, A. WINDAU1, M. V. PATEL2, N. DE SOUZA2, H. KHORAKIWALA2, P. C. APPELBAUM3;	1Case Western Reserve Univ, Cleveland, OH, 2Wockhardt Research Center, Aurangabad, India, 3Hershey Medical Center, Hershey, PA.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	543. WCK 919 - A New Respiratory Fluoroquinolone (FQ) with High In Vitro and In Vivo Potency against FQ Sensitive (FQS) and Resistant (FQR) Streptococci	M. V. PATEL1, S. V. GUPTE2, S. K. AGARWAL2, K. SREENIVAS2, S. C. NAIR2, H. F. KHORAKIWALA2, P. C. APPLEBAUM3, M. R. JACOBS4, N. J. DE SOUZA2;	1Wockhardt Research Centre, Aurangabad, India, 2WOCKHARDT RESEARCH CENTRE, AURANGABAD, India, 3Hershey Medical Centre, Hershey, PA, 4Case Western University, Cleveland, OH.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	544. WCK 919 - a New Respiratory Fluoroquinolone (FQ) with Potent Antistaphylococcal activity and an Ability to Overcome NorA Mediated FQ Efflux	S. K. AGARWAL, M. V. PATEL, S.V. GUPTE, Y. CHUGH, D. J. UPADHYAY, K. SREENIVAS, S.C. NAIR,M.A. JAFRI, N. J. DE SOUZA , H. F. KHORAKIWALA;	Wockhardt Research Centre, Aurangabad, India.
Sunday, 3:00 p.m. - 4:30 p.m.	051. Novel Quinolones I: WCK-771A and WCK-919	545. WCK 919 - a New Fluoroquinolone (FQ) with Excellent Potency for Gram +ve and Gram -ve Anaerobes	S. V. GUPTE, AND H. F. KHORAKIWALA, M. V. PATEL, S. K. AGARWAL, D. J. UPADHYAY, S.S. BHAGWAT, N. SHETTY, N. J. DE SOUZA;	Wockhardt Research Centre, Aurangabad, India.
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	547. DK-507k, a New 8-Methoxyquinolone: In Vitro and In Vivo Antibacterial Activities	T. OTANI, M. TANAKA, T. AKASAKA, Y. KUROSAKA, I. HAYAKAWA, K. SATO;	Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.	Poster Ansehen
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	551. DQ-113: A New Fluoroquinolone (FQ) with a Low Frequency of Mutational Resistance in MRSA	A. HOSSAIN, E. S. MOLAND, J. A. BLACK, S. A. CHARTRAND, N. D. HANSON, K. S. THOMSON;	Creighton Univ. Sch. of Med., Omaha, NE.
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	557. The In Vitro Activity of Non-Fluorinated Quinolones against Molecularly Characterized, Quinolone-Susceptible and -Resistant Isolates of Staphylococcus aureus and Streptococcus pneumoniae	M. E. JONES1, J. A. KARLOWSKY2, R. S. BLOSSER2, I. A. CRITCHLEY2, E. KARGINOVA2, F. J. SCHMITZ3, C. THORNSBERRY2, D. F. SAHM2;	1Focus Technologies/MRL, Hilversum, Netherlands, 2Focus Technologies/MRL, Herndon, VA, 3University Hospital, Dusseldorf, Germany.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	558. In Vitro Resistance Development to Non-Fluorinated Quinolones for Clinically Relevant Bacteria	E. M. KINCAID, P. M. KOENIGS;	Procter & Gamble Pharmaceuticals, Mason, OH.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	562. In Vivo Efficacy of Non-Fluorinated Quinolones in a Mouse Pulmonary Model of Infection	D. L. REICHART, J. E. EMIG, B. R. KUZMAK, K. E. GROPP, J. C. BIERMAN;	Procter & Gamble Pharmaceuticals, Mason, OH.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 8:30 a.m. - 11:00 a.m.	069. The Consequences of Antibiotic Resistance	652. Attached Staphylococcus epidermidis Has Reduced Susceptibility against Quinolones Independent from Biofilm Formation	JOHANNES K. M. KNOBLOCH, H. VON OSTEN, D. MACK;	Institute of Medical Microbiology and Immunology, Hamburg, Germany
Monday, 9:30 a.m. - 11:00 a.m.	073. Antimicrobial Resistance of Respiratory Pathogens	684. Longitudinal Surveillance of Antibiotic Resistance among Clinical Isolates of Community-Acquired Respiratory Tract Pathogens Collected in Asia in 1999/2000	M. INOUE;	Kitasato Univ., Kanagawa, Japan.
Monday, 9:30 a.m. - 11:00 a.m.	073. Antimicrobial Resistance of Respiratory Pathogens	692. Worldwide Surveillance of Antibiotic Resistance among Clinical Isolates of Streptococcus pneumoniae and Streptococcus pyogenes during 1999/2000	R. R. REINERT1, D. J. HOBAN2, D. FELMINGHAM3, J. PLUIM4;	1Natl. Reference Ctr. for Streptococci, Aachen, Germany, 2Health Sciences Ctr., Winnipeg, Canada, 3GR Micro, London, United Kingdom, 4Aventis Pharma, Bridgewater, NJ.
Monday, 9:30 a.m. - 11:00 a.m.	075. Pneumococci, Fluoroquinolones and Resistance	704. Rapidly Increasing Resistance of Streptococcus pneumoniae to Penicillin, Macrolides and Fluoroquinolones in a Canadian Teaching Hospital	H. G. ROBSON, J. LAVALLEE;	Royal Victoria Hospital, Montreal, Canada.
Monday, 9:30 a.m. - 11:00 a.m.	075. Pneumococci, Fluoroquinolones and Resistance	705. Activities of Respiratory Fluoroquinolones against Penicillin-Resistant S. pneumoniae Isolated in Six European Countries in 2000-01	M. E. JONES1, J. A. KARLOWSKY2, I. A. CRITCHLEY2, K. MURFITT2, R. S. BLOSSER2, C. THORNSBERRY2, D. F. SAHM2;	1Focus Technologies/MRL, Hilversum, Netherlands, 2Focus Technologies/MRL, Herndon, VA.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	075. Pneumococci, Fluoroquinolones and Resistance	707. Increasing Resistance of Streptococcus pneumoniae to Ciprofloxacin in the Province of Quebec, Canada	K. WEISS1, C. RESTIERI1, I. LECORRE2, P. DOLCE3, L. A. GALARNEAU4, P. HARVEY5, JF PARADIS2, H. SENAY2, D. E. LOW6, C. LAFERRIERE2;	1Hopital Maisonneuve-Rosemont, Montreal, Canada, 2The Gram Network, Montreal, Canada, 3The GRAM Network, Montreal, Canada, 4The Gram Network, Montreal, PQ, Canada, 5Hopital Maisonneuve-Rosemont, Montreal, PQ, Canada, 6Mount Sinai Hospital, Toronto, Canada.	Poster Ansehen
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	710. In Vitro Activity of BMS-284756 against Chlamydia trachomatis (Ct) and Recent Clinical Isolates of Chlamydia pneumoniae (Cpn)	P. M. ROBLIN, T. REZNIK, A. KUTLIN, M. R. HAMMERSCHLAG;	SUNY Downstate Medical Center, Brooklyn, NY.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	711. BMS 284756 Demonstrates Potent Activity against Canadian Lower Respiratory Tract Infection (RTI) Pathogens Isolated in 1999-2001	G. G. ZHANEL1, L. PALATNICK1, B. WESHNOWESKI1, H. SMITH2, K. NICHOL1, D. J. HOBAN1;	1Health Sciences Centre, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	712. Comparison of the Novel Des-Fluoro(6) Quinolone BMS-284756 to Different Fluoroquinolones (FQ) against Isogenic Pairs of FQ-Susceptible and FQ–Resistant Gram-Positive Pathogens	J. M. ENTENZA, M. GIDDEY, M. P. GLAUSER, P. MOREILLON;	CHUV, Lausanne, Switzerland.
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	714. Activity of BMS-284756 Desquinolone (DES) against Bacteroides fragilis Group Compared to that of Two Fluoroquinolones and Other Antianaerobic Agents	DAVID R. SNYDMAN, L. A. MCDERMOTT, N. V. JACOBUS;	New England Medical Center, Boston, MA	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	715. In Vitro Activity of BMS 2847576 against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities	MANDY WOOTTON1, A. R. NOEL1, A. P. MACGOWAN1, R. A. HOWE1, T. R. WALSH2, P. M. BENNETT2;	1BCARE, Bristol, United Kingdom, 2University of Bristol, Bristol, United Kingdom.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	716. Time-Kill Studies of the Anti-anaerobic Activity of BMS 284756, a New des-F(6)-Quinolone, Compared to Six Other Drugs	KIM L. CREDITO1, B. DEWASSE1, M. JACOBS2, P. APPELBAUM1;	1Hershey Medical Ctr, Hershey, PA, 2Case Western Res Univ, Cleveland, OH.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	718. Comparative In Vitro Activity of BMS-284756 against Gram Positive Clinical Isolates	M. BASSETTI, V.T. ANDRIOLE, L. M. DEMBRY, D. A. CALLAN, P. A. FARREL;	Yale Univ. Sch.of Med. and Yale New Haven Hosp., New Haven, CT.	Poster Ansehen
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	719. Activity of BMS-284756 and Four Fluoroquinolones against Streptococcus pneumoniae Exhibiting an Efflux Pump	F. J. BOSWELL, J. M. ANDREWS, T. M. A. WELLER, R. WISE;	City Hospital, Birmingham, United Kingdom.	Poster Ansehen
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	724. Activity of Nalidixic Acid and 6 Fluoroquinolones against 315 Isolates of Salmonella no Thypi	O. LOPEZ1, C. RODRIGUEZ-AVIAL2, I. RODRIGUEZ-AVIAL2, JUAN J. PICAZO2;	1Hospital Clinico San Carlos, Madrid, Spain, 2HOSPITAL CLINICO SAN CARLOS, MADRID, Spain.	Poster Ansehen
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	730. Comparative In Vitro Activity of Four Respiratory Fluoroquinolones (Resp-FQ) against Clinical Isolates of Strains of Streptococcus pneumoniae (SP)	DAVID C. RICHARDSON1,2, R. J. DAVIDSON3, L. A. MANDELL4, K. WEISS5, D. BAST2,1, J. DE AZAVEDO2,1, D. E. LOW2,1;	1Univ. Toronto, Toronto, ON, Canada, 2Toronto Med. Lab., Mount Sinai Hosp., Toronto, ON, Canada, 3Queen Elizabeth II Health Sci. Ctr, Dalhousie Univ., Halifax, ON, Canada, 4Henderson Site, Hamilton Health Sci. Corp., McMaster Univ., Hamilton, ON, Canada, 5Hopital Maisonneuve Rosemont, Montreal, PQ, Canada.
Monday, 9:30 a.m. - 11:00 a.m.	076. BMS-284756 and Other Fluoroquinolones In Vitro	734. Susceptibility of Anaerobic and Microaerophilic Microorganisms from Human Periodontal Infections and Oral Surgery Material to Moxifloxacin and Selected Substances	CLAUDIA NONNENMACHER, REINIER MUTTERS;	Institute for Medical Microbiology and Hygiene, Philipps University, Marburg, Germany.
Monday, 11:00 a.m. - 12:30 noon	080. Endocarditis and Vascular Infections	787. Efficacy of Moxifloxacin (MFX) against Experimental Endocarditis (EE) Due to Viridans Group Streptococci (VGS) with Various Resistant Phenotypes	J. M. ENTENZA, J. VOUILLAMOZ, M. GIDDEY, P. FRANCIOLI, P. MOREILLON;	CHUV, Lausanne, Switzerland.	Poster Ansehen (Teil 1)
					Poster Ansehen (Teil 2)
					Poster Ansehen (Teil 3)
Monday, 11:00 a.m. - 12:30 noon	085. Community-Acquired Pneumonia	854. Efficacy of Moxifloxacin (MXF) for Treatment of Community-Acquired Pneumonia (CAP) Due to Penicillin-Resistant Streptococcus pneumoniae (PRSP)	C. FOGARTY1, S. CHOUDHRI2, D. HAVERSTOCK2, P. JACKSON2, D. CHURCH2;	1Lung and Chest Medical Associates, Spartanburg, SC, 2Bayer Corporation, West Haven, CT.
Monday, 11:00 a.m. - 12:30 noon	085. Community-Acquired Pneumonia	865. Efficacy and Safety of Sequential (IV to PO) Moxifloxacin (MXF) for Treatment of Community-Acquired Pneumonia (CAP) Due to Atypical Pathogens	S. LARSEN1, S. CHOUDHRI2, D. HAVERSTOCK2, P. JACKSON2, D. CHURCH2;	1Fusion Clinical Trials, Red Bank, NJ, 2Bayer Corporation, West Haven, CT.
Monday, 1:30 p.m. - 3:00 p.m.	100. Ketolide Susceptibility Studies	1014. Activity of Telithromycin against Pneumococci with Known Quinolone Resistant Mechanisms	K. NAGAI1, D. HOELLMAN1, M. R. JACOBS2, P. C. APPELBAUM1;	1Hershey Med. Ctr., Hershey, PA, 2Case Western Reserve Univ., Cleveland, OH.
Monday, 1:30 p.m. - 3:00 p.m.	100. Ketolide Susceptibility Studies	1020. Comparative In Vitro Activity of Telithromycin, Macrolides, Quinolones and β-Lactams against Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae	J. DUBOIS, C. ST-PIERRE;	Novabyss Inc., Sherbrooke, PQ, Canada.	Poster Ansehen
Monday, 3:00 p.m. - 4:30 p.m.	122. Nosocomial Infections I: Staphylococcus aureus	1224. Risk Factors Associated with Methicillin-Resistant Staphylococcus aureus (MRSA)	R. A. VENEZIA, E. M. GRAFFUNDER, A. M. EVANS;	Albany Medical Center, Albany, NY.	Poster Ansehen
Tuesday, 8:30 a.m. - 11:00 a.m.	140. Resistance by Regulation of Gene Expression	1309. Efflux Mediated Fluoroquinolone Resistance in Streptococcus pneumoniae Correlates with Over-Expression of pmrA	N. NICKERSON1, M. HILTZ1, D. BAST2, J. DE AZAVEDO2, D. E. LOW2, R. J. DAVIDSON1;	1Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada, 2Mount Sinai Hospital, Toronto, ON, Canada.
Tuesday, 9:30 a.m. - 11:00 a.m.	147. Intracellular Pathogens	1376. Activities of New Macrolides and New Fluoroquinolones against Mycobacterium ulcerans Infection in Mice	A. BENTOUCHA1, J. ROBERT2, H. DEGA2, N. LOUNIS2, V. JARLIER2, J. GROSSET2;	1Bacteriologie, Pitie-Salpetriere, Paris, France, 2BACTERIOLOGIE, PITIE-SALPETRIERE, PARIS, France.
Tuesday, 11:00 a.m. - 12:30 noon	163. Animal Models of Mycoses	1608. Immunomodulatory and Protective Effects of Moxifloxacin against Candida albicans Induced Lung Infection in Cyclophosphamide Injected Mice	I. SHALIT, L. HOREV, I. FABIAN, N. KARIV, H. BLAU, I. SHECHTMAN, H. ALTARATS, Y. KLETTER;	Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Tuesday, 1:30 p.m. - 3:00 p.m.	171. Animal Models	1660. Efficacy of Gatifloxacin and Moxifloxacin Compared to Ciprofloxacin against Experimental Yersinia pestis Infection in Balb/c Mice	J. A. STEWARD, P. R. RUSSELL, T. J. G. BROOKS;	DERA, Salisbury, United Kingdom.	Poster Ansehen
Tuesday, 3:00 p.m. - 4:30 p.m.	189. Meningitis	1861. Evaluation of New Quinolones in Experimental Vancomycin-Tolerant Pneumococcal Meningitis	V. RODRIGUEZ-CERRATO1, C. C. MCCOIG1, J. SAAVEDRA1, T. BARTON2, I. C. MICHELOW1, R. D. HARDY1, K. BOWLWARE1, J. IGLEHART1, K. OLSEN1, G. H. MCCRACKEN JR.1;	1Univ. of Texas Southwestern Medical Center, Dallas, TX, 2Univ. of Texas southwestern Medical Center, Dallas, TX.	Poster Ansehen
Tuesday, 3:00 p.m. - 4:30 p.m.	190. Antimicrobial Use and Resistance	1865. Increasing Use of Fluoroquinolones and Susceptibility of Streptococcus pneumoniae over the Period 1994-2000	LUDO VERBIST, JAN VERHAEGEN, JOHAN VAN ELDERE, ISABELLE DEVENYNS, WILLY E. PEETERMANS;	University Hospital K.U.Leuven, Leuven, Belgium.
Tuesday, 3:00 p.m. - 4:30 p.m.	191. Enterococci of Human and Non-Human Origin	1877. Antimicrobial Resistance Phenotypes and Resistance Genes in Enterococcus spp. Isolated from Healthy Volunteers and Food Handlers in Spain	R. DEL CAMPO1, P. RUIZ-GARBAJOSA2, M. P. SÁNCHEZ-MORENO3, R. CANTON4, F. BAQUERO2, T. M. COQUE2;	1Hospital Ramon y Cajal, Madrid, Spain, 2HOSPITAL RAMON Y CAJAL, MADRID, Spain, 3Laboratorio Municipal de Higiene, Madrid, Spain, 4HOSPITAL RAMON Y CAJAL, madrid, Spain.
Wednesday, 8:30 a.m. - 10:00 a.m.	216. Pharmacodynamics of Antimicrobials I: In Vitro Models	2072. Comparative Fluoroquinolone (FQ) Pharmacodynamics(PD) against Common Gram Positive and Gram Negative Organisms over a Range of Creatine Clearance (CrCl)	K. ENZWEILER, K. LORENZ, J. BOSSO, R. WHITE;	Med. Univ. of S. Carolina, Charleston, SC.
Wednesday, 8:30 a.m. - 10:00 a.m.	216. Pharmacodynamics of Antimicrobials I: In Vitro Models	2076. Pharmacodynamics of Moxifloxacin vs Eythromycin against Intracellular in an In Vitro Kinetic Model	E. TANO, E. LÖWDIN, O. CARS;	University Hospital, Uppsala, Sweden.	Poster Ansehen
Wednesday, 8:30 a.m. - 10:00 a.m.	216. Pharmacodynamics of Antimicrobials I: In Vitro Models	2080. Different Integral Endpoints of the Anti-Staphylococcal Effect of Moxifloxacin and Levofloxacin in an In Vitro Dynamic Model	I. LUBENKO1, Y. PORTNOY1, S. VOSTROV1, S. ZINNER2, A. FIRSOV1;	1G. Gause Institute of New Antibiotics, Moscow, Russian Federation, 2Mount Auburn Hospital, Cambridge, MA.
Wednesday, 10:00 a.m. - 11:30 a.m.	225. Sepsis	2212. Cell Signallling via Toll Like Receptor 2 in Response to Streptococcus pneumoniae Is Enhanced by Sub-inhibitory Concentrations of Penicillin	L. J. EVANS1, A. C. PRIDMORE1, S. K. DOWER1, G. TILLOTSON2, R. C. READ1;	1Univ. Of Sheffield Med. Sch., Sheffield, United Kingdom, 2Univ. Of New York, New York, NY.	Poster Ansehen
Wednesday, 10:00 a.m. - 11:30 a.m.	230. In Vitro Susceptibility: Miscellaneous	2271. In Vitro Activity of Older and Newer Fluoroquinolones against Corynebacterium urealyticum	FRANCISCO JAVIER SÁNCHEZ HERNÁNDEZ1, JUAN LUIS MUÑOZ-BELLIDO1, Mª NIEVES GUTIÉRREZ ZUFIAURRE1, GENOVEVA YAGÜE GUIRAO2, Mª CARMEN M. TOLDOS2, BEGOÑA MORA PERIS3, MANUEL SEGOVIA HERNÁNDEZ3, JOSÉ ANGEL GARCÍA-RODRÍGUEZ4;	1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Morales Meseguer, Murcia, Spain, 3HOSPITAL MORALES MESEGUER, MURCIA, Spain, 4Kitasato University School of Medicine, Salamanca, Spain.
Wednesday, 10:00 a.m. - 11:30 a.m.	230. In Vitro Susceptibility: Miscellaneous	2274. In Vitro Activity of Fosfomycin in Combination with Anti-Staphylococcal Substances	FRANZ J. ALLERBERGER, K. GRIF, M.P. DIERICH, K. PFALLER, P. MIGLIOLI;	Inst. for Hygiene and Social Med., Innsbruck, Austria.